KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Equity (2020 - 2024)

AbCellera Biologics (ABCL) has disclosed Return on Equity for 5 consecutive years, with 0.04% as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Return on Equity rose 7.0% year-over-year to 0.04%, compared with a TTM value of 0.04% through Sep 2024, up 7.0%, and an annual FY2024 reading of 0.15%, down 2.0% over the prior year.
  • Return on Equity was 0.04% for Q3 2024 at AbCellera Biologics, up from 0.07% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.35% in Q4 2020 and bottomed at 0.13% in Q4 2023.
  • Average Return on Equity over 5 years is 0.09%, with a median of 0.14% recorded in 2021.
  • The sharpest move saw Return on Equity plummeted -31bps in 2023, then rose 7bps in 2024.
  • Year by year, Return on Equity stood at 0.35% in 2020, then tumbled by -56bps to 0.16% in 2021, then fell by -18bps to 0.13% in 2022, then crashed by -198bps to 0.13% in 2023, then skyrocketed by 66bps to 0.04% in 2024.
  • Business Quant data shows Return on Equity for ABCL at 0.04% in Q3 2024, 0.07% in Q2 2024, and 0.09% in Q1 2024.